Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02583919 · ClinicalTrials.gov registry record · Phase 2
Safety, Tolerability and Efficacy of ISIS-GCGRRx in Patients With Type 2 Diabetes
A Phase 2 study, sponsored by Ionis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 79
- Enrollment target
NCT02583919 is a Phase 2 study that has completed, run by Ionis Pharmaceuticals. The registered enrollment target is 79 participants.
The verdict
NCT02583919, a Phase 2 study, has completed, sponsored by Ionis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 79 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy, safety, and tolerability of ISIS-GCGRRx in combination with metformin versus placebo
Interventions
- DRUG Placebo
- DRUG ISIS-GCGRRx- Dose Level 1
- DRUG ISIS-GCGRRx- Dose Level 2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 79 participants |
| Start Date | 2015-09 |
| Est. Completion | 2017-05-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02583919
The ClinicalTrials.gov registry entry for NCT02583919 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 79 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ionis Pharmaceuticals, which has 76 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02583919 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02583919 about?
NCT02583919 is a clinical study titled "Safety, Tolerability and Efficacy of ISIS-GCGRRx in Patients With Type 2 Diabetes". The purpose of this study is to evaluate the efficacy, safety, and tolerability of ISIS-GCGRRx in combination with metformin versus placebo
What is the current status of trial NCT02583919?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 79 participants. The study started on 2015-09. Estimated completion is 2017-05-11.
What interventions are being tested in trial NCT02583919?
The interventions under investigation include: Placebo (DRUG), ISIS-GCGRRx- Dose Level 1 (DRUG), ISIS-GCGRRx- Dose Level 2 (DRUG).
Who is sponsoring clinical trial NCT02583919?
This trial is sponsored by Ionis Pharmaceuticals, which has 76 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.